Show simple item record

dc.contributor.authorSmith, Karen L.
dc.contributor.authorJessop, David S.
dc.contributor.authorFinn, David P.
dc.date.accessioned2019-03-29T15:31:52Z
dc.date.available2019-03-29T15:31:52Z
dc.date.issued2009-07-07
dc.identifier.citationSmith, Karen L., Jessop, David S., & Finn, David P. (2009). Modulation of stress by imidazoline binding sites: Implications for psychiatric disorders. Stress, 12(2), 97-114. doi: 10.1080/10253890802302908en_IE
dc.identifier.issn1607-8888
dc.identifier.urihttp://hdl.handle.net/10379/15080
dc.description.abstractIn this review, we present evidence for the involvement of imidazoline binding sites (IBS) in modulating responses to stress, through central control of monoaminergic and hypothalamo-pituitary-adrenal (HPA) axis activity. Pharmacological and physiological evidence is presented for differential effects of different IBS subtypes on serotoninergic and catecholaminergic pathways involved in control of basal and stress-stimulated HPA axis activity. IBS ligands can modulate behavioural and neuroendocrine responses in animal models of stress, depression and anxiety, and a body of evidence exists for alterations in central IBS expression in psychiatric patients, which can be normalised partially or fully by treatment with antidepressants. Dysfunction in monoaminergic systems and the HPA axis under basal and stress-induced activation has been extensively reported in psychiatric illnesses. On the basis of the literature, we suggest a potential therapeutic role for selective IBS ligands in the treatment of depression and anxiety disorders.en_IE
dc.description.sponsorshipThis work was supported by a grant from Science Foundation Ireland.en_IE
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.publisherTaylor & Francisen_IE
dc.relation.ispartofStressen
dc.subject5-HTen_IE
dc.subjectdepressionen_IE
dc.subjecthypothalamo-pituitary-adrenal axisen_IE
dc.subjectimidazoline binding sitesen_IE
dc.subjectmonoamine neuronesen_IE
dc.subjectnoradrenalineen_IE
dc.subjectsympathetic nervous systemen_IE
dc.subjectCORTICOTROPIN-RELEASING-FACTORen_IE
dc.subjectCLONIDINE-DISPLACING SUBSTANCEen_IE
dc.subjectPITUITARY-ADRENAL AXISen_IE
dc.subjectROSTRAL VENTROLATERAL MEDULLAen_IE
dc.subjectLOCUS-COERULEUS NEURONSen_IE
dc.subjectMONOAMINE-OXIDASE-Aen_IE
dc.subjectFORCED SWIM TESTen_IE
dc.subjectPROTEIN-KINASE PHOSPHORYLATIONen_IE
dc.subjectIMIDAZOLEACETIC ACID-RIBOTIDEen_IE
dc.subjectPC12 PHEOCHROMOCYTOMA CELLSen_IE
dc.titleModulation of stress by imidazoline binding sites: Implications for psychiatric disordersen_IE
dc.typeArticleen_IE
dc.date.updated2019-03-27T14:20:55Z
dc.identifier.doi10.1080/10253890802302908
dc.local.publishedsourcehttps://doi.org/10.1080/10253890802302908en_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funderScience Foundation Irelanden_IE
dc.internal.rssid2180421
dc.local.contactDavid Finn, Dept. Of Pharmacology &, Therapeutics, Nui, Galway. 5280 Email: david.finn@nuigalway.ie
dc.local.copyrightcheckedYes
dc.local.versionACCEPTED
nui.item.downloads71


Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:

Thumbnail

This item appears in the following Collection(s)

Show simple item record